Top

Published in:

01-09-2012 | Decompensated Heart Failure (MM Givertz, Section editor)

Congestion Is the Driving Force Behind Heart Failure

Author: Maya Guglin

Published in: Current Heart Failure Reports | Issue 3/2012

Abstract

Increased filling pressures, or congestion, cause symptoms of heart failure and lead to hospitalizations. A higher rate of hospitalizations determines higher mortality. The most reliable way to decrease admissions is to monitor for signs of congestion, by history and exam, intracardiac pressures or biomarkers, and to modify treatment based on these data. The role of congestion is best understood by comparison of heart failure with preserved and reduced ejection fraction. The morbidity and mortality in both conditions is almost identical. Decreased cardiac output and ventricular remodeling play a major role in patients with decreased ejection fraction but not in those with preserved ejection fraction. The key factor that is present in both conditions and determines their similarity is congestion. Decongestion, or fluid removal, is the most effective treatment for heart failure regardless of ejection fraction. Being the driving force of heart failure, congestion should be the focus of clinical and hemodynamic monitoring and therapy.

Yancy CW, Fonarow GC, Committee ASA. Quality of care and outcomes in acute decompensated heart failure: the ADHERE registry. Curr Heart Fail Rep. 2004;1:121–8.PubMedCrossRef

Tallaj JAP, Aaron M, Abraham W, Heywood JBR, Cho Y, Bennett T. Relationship between right ventricular pressures and heart failure events in patients with heart failure. J Card Fail. 2007;13:S178–9.CrossRef

Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008;118:1433–41.PubMedCrossRef

•• Stevenson LW, Zile M, Bennett TD, Kueffer FJ, Jessup ML, Adamson P, et al. Chronic ambulatory intracardiac pressures and future heart failure events. Circ Heart Fail. 2010;3:580–7. This paper demonstrates the importance of congestion and its management for hospital admissions.PubMedCrossRef

Adamson PB, Magalski A, Braunschweig F, Bohm M, Reynolds D, Steinhaus D, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol. 2003;41:565–71.PubMedCrossRef

•• Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658–66. This article on the results of the CHAMPION trial demonstrates reduction in heart failure admission rates with hemodynamic monitoring.PubMedCrossRef

• Sharma GV, Woods PA, Lindsey N, O’Connell C, Connolly L, Joseph J, et al. Noninvasive monitoring of left ventricular end-diastolic pressure reduces rehospitalization rates in patients hospitalized for heart failure: a randomized controlled trial. J Card Fail. 2011;17:718–25. This paper further develops the idea of benefits of guiding the therapy in heart failure by hemodynamic parameters.PubMedCrossRef

Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol. 2007;49:1733–9.PubMedCrossRef

•• Januzzi Jr JL, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58:1881–9. This article is interesting in several respects: it shows the importance of BNP-guided strategy, and highlights the interactions between systolic function and congestion.PubMedCrossRef

10.

Lee DAP, Stukel T, Alter D, Chong A, PArker J, Tu J. “Dose-dependent” impact of recurrent cardiac events on mortality in patients with heart failure. Am J Med. 2009;122:162.e1–.e9.CrossRef

11.

•• Guglin M. Key role of congestion in natural history of heart failure. Int J Gen Med. 2011;4:585–91. This paper underscores the inconsistencies in current understanding of the concept of heart failure, and suggests a new model explaining all varieties of the disease.PubMed

12.

Damman K, Voors AA, Hillege HL, Navis G, Lechat P, van Veldhuisen DJ, et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Hear Fail. 2010;12:974–82.CrossRef

13.

Kjaergaard J, Akkan D, Iversen KK, Kjoller E, Kober L, Torp-Pedersen C, et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007;99:1146–50.PubMedCrossRef

14.

Kjaergaard J, Akkan D, Iversen KK, Kober L, Torp-Pedersen C, Hassager C. Right ventricular dysfunction as an independent predictor of short- and long-term mortality in patients with heart failure. Eur J Heart Fail. 2007;9:610–6.PubMedCrossRef

15.

•• Bursi F, McNallan SM, Redfield MM, Nkomo VT, Lam CS, Weston SA, et al. Pulmonary pressures and death in heart failure a community study. J Am Coll Cardiol. 2012;59:222–31. This study from Mayo Clinic shows the importance of pulmonary hypertension as a prognostic factor in heart failure.PubMedCrossRef

16.

Neuman Y, Kotliroff A, Bental T, Siegel RJ, David D, Lishner M. Pulmonary artery pressure and diastolic dysfunction in normal left ventricular systolic function. Int J Cardiol. 2007.

17.

Dini FL, Nuti R, Barsotti L, Baldini U, Dell’Anna R, Micheli G. Doppler-derived mitral and pulmonary venous flow variables are predictors of pulmonary hypertension in dilated cardiomyopathy. Echocardiography. 2002;19:457–65.PubMedCrossRef

18.

Enriquez-Sarano M, Rossi A, Seward JB, Bailey KR, Tajik AJ. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol. 1997;29:153–9.PubMedCrossRef

19.

Guglin M. Pulmonary vasodilation in acute and chronic heart failure: empiricism and evidence. Curr Heart Fail Rep. 2011;8:219–25.PubMedCrossRef

20.

• Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164–74. This study demonstrated hemodynamic and clinical benefits of sildenafil in heart failure with preserved systolic function.PubMedCrossRef

21.

Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13:422–30.PubMedCrossRef

22.

Maeder MHD, Kaye D. Does tricuspid regurgitation contribute to renal dysfunction in patients with heart failure. J Card Fail. 2008;14:S84.CrossRef

23.

Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–96.PubMedCrossRef

24.

Guglin M, Rivero A, Matar F, Garcia M. Renal dysfunction in heart failure is due to congestion but not low output. Clin Cardiol. 2011;34:113–6.PubMedCrossRef

25.

Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9.PubMedCrossRef

26.

Ansari M, Alexander M, Tutar A, Massie BM. Incident cases of heart failure in a community cohort: importance and outcomes of patients with preserved systolic function. Am Heart J. 2003;146:115–20.PubMedCrossRef

27.

Berry C, Hogg K, Norrie J, Stevenson K, Brett M, McMurray J. Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart. 2005;91:907–13.PubMedCrossRef

28.

Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, et al. Systolic and diastolic heart failure in the community. JAMA: J Am Med Assoc. 2006;296:2209–16.CrossRef

29.

Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol. 2007;50:768–77.PubMedCrossRef

30.

Varela-Roman A, Gonzalez-Juanatey JR, Basante P, Trillo R, Garcia-Seara J, Martinez-Sande JL, et al. Clinical characteristics and prognosis of hospitalised inpatients with heart failure and preserved or reduced left ventricular ejection fraction. Heart. 2002;88:249–54.PubMedCrossRef

31.

Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260–9.PubMedCrossRef

32.

Varela-Roman A, Grigorian L, Barge E, Bassante P, de la Pena MG, Gonzalez-Juanatey JR. Heart failure in patients with preserved and deteriorated left ventricular ejection fraction. Heart (British Cardiac Society). 2005;91:489–94.CrossRef

33.

Senni M, Redfield MM. Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol. 2001;38:1277–82.PubMedCrossRef

34.

Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948–55.PubMedCrossRef

35.

Sweitzer NK, Lopatin M, Yancy CW, Mills RM, Stevenson LW. Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55 %) versus those with mildly reduced (40 % to 55 %) and moderately to severely reduced (<40 %) fractions. Am J Cardiol. 2008;101:1151–6.PubMedCrossRef

36.

Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2011. doi:10.1093/eurheartj/ehr254

37.

Grigorian-Shamagian L, Otero Ravina F, Abu Assi E, Vidal Perez R, Teijeira-Fernandez E, Varela Roman A, et al. Why and when do patients with heart failure and normal left ventricular ejection fraction die? Analysis of >600 deaths in a community long-term study. Am Hear J. 2008;156:1184–90.CrossRef

38.

Al-Khatib SM, Shaw LK, O’Connor C, Kong M, Califf RM. Incidence and predictors of sudden cardiac death in patients with diastolic heart failure. J Cardiovasc Electrophysiol. 2007;18:1231–5.PubMedCrossRef

39.

Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003;362:777–81.PubMedCrossRef

40.

Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–45.PubMedCrossRef

41.

Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–67.PubMedCrossRef

42.

Andrew P. Diastolic heart failure demystified. Chest. 2003;124:744–53.PubMedCrossRef

43.

Maurer MS, King DL, El-Khoury Rumbarger L, Packer M, Burkhoff D. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. J Card Fail. 2005;11:177–87.PubMedCrossRef

44.

Maurer MS, Burkhoff D, Fried LP, Gottdiener J, King DL, Kitzman DW. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the cardiovascular health study. J Am Coll Cardiol. 2007;49:972–81.PubMedCrossRef

45.

Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115:1982–90.PubMedCrossRef

46.

Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation. 2002;105:1503–8.PubMedCrossRef

47.

Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation. 2005;112:2254–62.PubMedCrossRef

48.

Victor BM, Barron JT. Diastolic heart failure versus diastolic dysfunction: difference in renal function. Clin Cardiol. 2010;33:770–4.PubMedCrossRef

49.

Bowling CB, Feller MA, Mujib M, Pawar PP, Zhang Y, Ekundayo OJ, et al. Relationship between stage of kidney disease and incident heart failure in older adults. Am J Nephrol. 2011;34:135–41.PubMedCrossRef

50.

Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: a community perspective. Circ Heart Fail. 2008;1:91–7.PubMedCrossRef

51.

Zafrir B, Paz H, Wolff R, Salman N, Merhavi D, Lewis BS, et al. Mortality rates and modes of death in heart failure patients with reduced versus preserved systolic function. Eur J Intern Med. 2011;22:53–6.PubMedCrossRef

52.

Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the irbesartan in heart failure with preserved ejection fraction study (I-preserve) trial. Circulation. 2010;121:1393–405.PubMedCrossRef

53.

Grigorian Shamagian L, Gonzalez-Juanatey JR, Roman AV, Acuna JM, Lamela AV. The death rate among hospitalized heart failure patients with normal and depressed left ventricular ejection fraction in the year following discharge: evolution over a 10-year period. Eur Heart J. 2005;26:2251–8.PubMedCrossRef

54.

Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll Cardiol. 2006;47:76–84.PubMedCrossRef

55.

Richardson A, Bayliss J, Scriven AJ, Parameshwar J, Poole-Wilson PA, Sutton GC. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet. 1987;2:709–11.PubMedCrossRef

56.

Cowley AJ, Stainer K, Wynne RD, Rowley JM, Hampton JR. Symptomatic assessment of patients with heart failure: double-blind comparison of increasing doses of diuretics and captopril in moderate heart failure. Lancet. 1986;2:770–2.PubMedCrossRef

57.

van Kraaij DJ, Jansen RW, Bruijns E, Gribnau FW, Hoefnagels WH. Diuretic usage and withdrawal patterns in a Dutch geriatric patient population. J Am Geriatr Soc. 1997;45:918–22.PubMed

58.

Mathur PN, Pugsley SO, Powles AC, McEwan MP, Campbell EJ. Effect of diuretics on cardiopulmonary performance in severe chronic airflow obstruction. A controlled clinical trial. Arch Intern Med. 1984;144:2154–7.PubMedCrossRef

59.

Andrews R, Charlesworth A, Evans A, Cowley AJ. A double-blind, cross-over comparison of the effects of a loop diuretic and a dopamine receptor agonist as first line therapy in patients with mild congestive heart failure. Eur Heart J. 1997;18:852–7.PubMedCrossRef

60.

Grinstead WC, Francis MJ, Marks GF, Tawa CB, Zoghbi WA, Young JB. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. Am J Cardiol. 1994;73:881–6.PubMedCrossRef

61.

Ahmed A, Young JB, Love TE, Levesque R, Pitt B. A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure. Int J Cardiol. 2008;125:246–53.PubMedCrossRef

62.

Neuberg GW, Miller AB, O’Connor CM, Belkin RN, Carson PE, Cropp AB, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31–8.PubMedCrossRef

63.

Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759–64.PubMedCrossRef

64.

Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705–8.PubMedCrossRef

65.

• Guglin M. Reappraisal of the role of diuretics in heart failure. Cardiol Rev. 2009;17:56–9. This is a critical analysis of the existing literature on diuretics in heart failure.PubMedCrossRef

66.

Mielniczuk LM, Tsang SW, Desai AS, Nohria A, Lewis EF, Fang JC, et al. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail. 2008;14:388–93. This study introduces the concept that high dose of diuretics is a marker but not the cause of instability in heart failure.PubMedCrossRef

67.

Guglin M. Diuretics as pathogenetic treatment for heart failure. Int J Gen Med. 2011;4:91–8.PubMed

68.

•• Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122:265–72. This is a subanalysis of the ESCAPE trial showing mortality benefits from aggressive diuresis.PubMedCrossRef

69.

Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805.PubMedCrossRef

70.

Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012;59:442–51.PubMedCrossRef

71.

Rubboli A, Sobotka PA, Euler DE. Effect of acute edema on left ventricular function and coronary vascular resistance in the isolated rat heart. Am J Physiol. 1994;267:H1054–61.PubMed

72.

Parrinello G, Paterna S, Di Pasquale P, Torres D, Mezzero M, Cardillo M, et al. Changes in estimating echocardiography pulmonary capillary wedge pressure after hypersaline plus furosemide versus furosemide alone in decompensated heart failure. J Card Fail. 2011;17:331–9.PubMedCrossRef

73.

Ip JE, Cheung JW, Park D, Hellawell JL, Stein KM, Iwai S, et al. Temporal associations between thoracic volume overload and malignant ventricular arrhythmias: a study of intrathoracic impedance. J Cardiovasc Electrophysiol. 2011;22:293–9.PubMedCrossRef

74.

Moore HJ, Peters MN, Franz MR, Karasik PE, Singh SN, Fletcher RD. Intrathoracic impedance preceding ventricular tachyarrhythmia episodes. Pacing Clin Electrophysiol. 2010;33:960–6.PubMed

Title: Congestion Is the Driving Force Behind Heart Failure
Author: Maya Guglin
Publication date: 01-09-2012
Publisher: Current Science Inc.
Published in: Current Heart Failure Reports / Issue 3/2012
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-012-0093-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Congestion Is the Driving Force Behind Heart Failure

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Cardiac Side Effects of Anticancer Treatments: New Mechanistic Insights

Cardiac Role of Cyclic-GMP Hydrolyzing Phosphodiesterase Type 5: From Experimental Models to Clinical Trials

Diuretic Dosing in Acute Decompensated Heart Failure: Lessons from DOSE

New Treatment Options for Late Na Current, Arrhythmias, and Diastolic Dysfunction

16-kDa Prolactin and Bromocriptine in Postpartum Cardiomyopathy

Erratum to: Galectin-3 in Cardiac Remodeling and Heart Failure

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page